Advertisement
EXEL vs RPRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and RPRX is a Hold.
EXEL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EXEL turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on EXEL as a result. In 65 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
Following a +5.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 204 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 166 of 268 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.843) is normal, around the industry mean (26.782). P/E Ratio (18.355) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (437.542).
RPRX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RPRX turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 32 of 52 cases over the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RPRX's RSI Oscillator exited the oversold zone, 14 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 54%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 50 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 176 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for RPRX crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RPRX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.804) is normal, around the industry mean (26.782). P/E Ratio (31.382) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). RPRX's Dividend Yield (0.016) is considerably higher than the industry average of (0.000). P/S Ratio (12.870) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
EXEL | RPRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 27 | |
SMR RATING 1..100 | 23 | 97 | |
PRICE GROWTH RATING 1..100 | 37 | 40 | |
P/E GROWTH RATING 1..100 | 45 | 6 | |
SEASONALITY SCORE 1..100 | 48 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RPRX's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for EXEL (80) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than EXEL’s over the last 12 months.
EXEL's Profit vs Risk Rating (5) in the Biotechnology industry is in the same range as RPRX (27) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to RPRX’s over the last 12 months.
EXEL's SMR Rating (23) in the Biotechnology industry is significantly better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew significantly faster than RPRX’s over the last 12 months.
EXEL's Price Growth Rating (37) in the Biotechnology industry is in the same range as RPRX (40) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to RPRX’s over the last 12 months.
RPRX's P/E Growth Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for EXEL (45) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than EXEL’s over the last 12 months.
| EXEL | RPRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 57% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 67% | 1 day ago 59% |
| Advances ODDS (%) | 2 days ago 67% | 1 day ago 56% |
| Declines ODDS (%) | 4 days ago 59% | 11 days ago 49% |
| BollingerBands ODDS (%) | 1 day ago 56% | 1 day ago 61% |
| Aroon ODDS (%) | 1 day ago 62% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 2 FA rating(s) are green while RPRX’s FA Score has 3 green FA rating(s).
- EXEL’s FA Score: 2 green, 3 red.
- RPRX’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 4 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s).
- EXEL’s TA Score: 4 bullish, 4 bearish.
- RPRX’s TA Score: 5 bullish, 5 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +3.96% price change this week, while RPRX (@Biotechnology) price change was +7.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
EXEL is expected to report earnings on Nov 03, 2026.
RPRX is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EXEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.
| Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
|---|---|---|---|---|
| EXEL | 100% | -0.95% | ||
| INCY - EXEL | 49% Loosely correlated | -0.18% | ||
| MIRM - EXEL | 42% Loosely correlated | -2.73% | ||
| GMAB - EXEL | 39% Loosely correlated | -2.17% | ||
| RPRX - EXEL | 38% Loosely correlated | +2.25% | ||
| ACAD - EXEL | 35% Loosely correlated | -2.99% | ||
More | ||||